<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843972</url>
  </required_header>
  <id_info>
    <org_study_id>1334.1</org_study_id>
    <secondary_id>2012-005721-67</secondary_id>
    <nct_id>NCT01843972</nct_id>
  </id_info>
  <brief_title>Safety of Single Rising Doses and Relative Bioavailability of BI 691751</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 691751 in Healthy Male Volunteers in a Randomised, Single-blind, Placebo-controlled Design (Part I) and Investigation of Relative Bioavailability of BI 691751 Given as Tablet and Oral Solution to Healthy Male Subjects in an Open, Randomised, Single-dose, Single Period Parallel Group Design (Part II).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of single
      rising doses of BI 691751 in healthy male subjects (part I).

      To investigate the relative bioavailability of BI 691751 given as tablet versus oral solution
      (part II)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-72h (Part II)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h and 72h after drug administration</time_frame>
    <description>AUC0-72h (area under the concentration-time curve of the analyte of BI 691751 in plasma over the time interval from 0 to 72 h) (part II).
PPS-BA included all subjects in the TS who were randomised to the BA part, who provided at least one observation for at least one primary endpoint, had no important protocol violations relevant for the statistical evaluation of BA and did not experience emesis at or before twice the median tmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Part II)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug administration</time_frame>
    <description>Cmax (maximum measured concentration of the analyte of BI 691751 in plasma) (part II)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Subjects With Drug-related Adverse Events (Part I)</measure>
    <time_frame>Part I: 'Day1 to Day21 for Dose 1, 2,3 &amp;4 and Day1 to Day45 for Dose group 5,6 &amp; 7</time_frame>
    <description>Frequency of subjects with drug-related Adverse Events (AEs) (Part I)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (Part I)</measure>
    <time_frame>for dose 1 &amp; 2: up to 168h, for dose 3 &amp; 4: up to 240h, for dose 5 to 8: up to 720h</time_frame>
    <description>Cmax (maximum measured concentration of BI 691751 in plasma) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (Part I)</measure>
    <time_frame>for dose 1 &amp; 2: up to 168 hours (h), for dose 3 &amp; 4: up to 240h, for dose 5 to 8: up to 720h</time_frame>
    <description>AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 extrapolated to infinity) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>Part 1: for dose 1 &amp; 2: up to 168 hours (h), for dose 3 &amp; 4: up to 240h, for dose 5 to 7: up to 720h; Part 2: up to 720h</time_frame>
    <description>AUC0-tz (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 up to the last quantifiable data point) (Part I and Part II)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (Part I)</measure>
    <time_frame>for dose 1 &amp; 2: up to 168 hours (h), for dose 3 &amp; 4: up to 240h, for dose 5 to 8: up to 720h</time_frame>
    <description>t1/2 (terminal half-life of the analyte of BI 691751 in plasma) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (Part I)</measure>
    <time_frame>for dose 1 &amp; 2: up to 168 hours (h), for dose 3 &amp; 4: up to 240h, for dose 5 to 8: up to 720h</time_frame>
    <description>tmax (time from dosing to maximum measured concentration of BI 691751) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 691751 dose 2 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 3 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 4 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 5 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 6 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 7 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751dose 1 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (part I)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 tablet (part II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as 1 tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 solution (part II)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 6</description>
    <arm_group_label>BI 691751 dose 6 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution</description>
    <arm_group_label>BI 691751 solution (part II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 2</description>
    <arm_group_label>BI 691751 dose 2 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 5</description>
    <arm_group_label>BI 691751 dose 5 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>1 tablet</description>
    <arm_group_label>BI 691751 tablet (part II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 3</description>
    <arm_group_label>BI 691751 dose 3 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 69175, dose 4</description>
    <arm_group_label>BI 691751 dose 4 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 7</description>
    <arm_group_label>BI 691751 dose 7 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 69175, dose 1</description>
    <arm_group_label>BI 691751dose 1 (part I)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male subjects

          2. Subjects must be able to understand and comply with study requirements

          3. Age from 18 to 55 years

          4. BMI range: from 18.5 to 29.9 kg/m2

          5. Known genotype as specified in the study protocol

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1334.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <results_first_submitted>November 11, 2015</results_first_submitted>
  <results_first_submitted_qc>February 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Part I)</title>
          <description>placebo solution
Placebo: placebo solution</description>
        </group>
        <group group_id="P2">
          <title>BI 691751 Dose 1 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
        </group>
        <group group_id="P3">
          <title>BI 691751 Dose 2 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
        </group>
        <group group_id="P4">
          <title>BI 691751 Dose 3 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
        </group>
        <group group_id="P5">
          <title>BI 691751 Dose 4 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
        </group>
        <group group_id="P6">
          <title>BI 691751 Dose 5 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
        </group>
        <group group_id="P7">
          <title>BI 691751 Dose 6 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
        </group>
        <group group_id="P8">
          <title>BI 691751 Dose 7 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
        </group>
        <group group_id="P9">
          <title>BI 691751 Tablet (Part II)</title>
          <description>single dose given as 1 tablet
BI 691751: 1 tablet (10 mg)</description>
        </group>
        <group group_id="P10">
          <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
          <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): includes all subjects who were documented to have taken at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Part I)</title>
          <description>placebo solution
Placebo: placebo solution</description>
        </group>
        <group group_id="B2">
          <title>BI 691751dose 1 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
        </group>
        <group group_id="B3">
          <title>BI 691751 Dose 2 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
        </group>
        <group group_id="B4">
          <title>BI 691751 Dose 3 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
        </group>
        <group group_id="B5">
          <title>BI 691751 Dose 4 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
        </group>
        <group group_id="B6">
          <title>BI 691751 Dose 5 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
        </group>
        <group group_id="B7">
          <title>BI 691751 Dose 6 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
        </group>
        <group group_id="B8">
          <title>BI 691751 Dose 7 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
        </group>
        <group group_id="B9">
          <title>BI 691751 Tablet (Part II)</title>
          <description>single dose given as 1 tablet
BI 691751: 1 tablet (10 mg)</description>
        </group>
        <group group_id="B10">
          <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
          <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="17"/>
            <count group_id="B10" value="12"/>
            <count group_id="B11" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="8.2"/>
                    <measurement group_id="B2" value="31.2" spread="8.0"/>
                    <measurement group_id="B3" value="32.0" spread="8.4"/>
                    <measurement group_id="B4" value="34.5" spread="6.8"/>
                    <measurement group_id="B5" value="26.5" spread="5.2"/>
                    <measurement group_id="B6" value="37.5" spread="6.0"/>
                    <measurement group_id="B7" value="29.2" spread="2.6"/>
                    <measurement group_id="B8" value="30.2" spread="8.0"/>
                    <measurement group_id="B9" value="32.2" spread="9.3"/>
                    <measurement group_id="B10" value="35.8" spread="10.2"/>
                    <measurement group_id="B11" value="31.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="17"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-72h (Part II)</title>
        <description>AUC0-72h (area under the concentration-time curve of the analyte of BI 691751 in plasma over the time interval from 0 to 72 h) (part II).
PPS-BA included all subjects in the TS who were randomised to the BA part, who provided at least one observation for at least one primary endpoint, had no important protocol violations relevant for the statistical evaluation of BA and did not experience emesis at or before twice the median tmax.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h and 72h after drug administration</time_frame>
        <population>Per protocol set for evaluation of bioavailability (PPS-BA). Only subjects with calculable PK parameter were analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751 Tablet Extensive Metabolizers (Part II)</title>
            <description>single dose given as 1 tablet; extensive metabolizers;
BI 691751: 1 tablet (10 mg)</description>
          </group>
          <group group_id="O2">
            <title>BI 691751 Tablet Poor Metabolizers (Part II)</title>
            <description>single dose given as 1 tablet; poor metabolizers;
BI 691751: 1 tablet (10 mg)</description>
          </group>
          <group group_id="O3">
            <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
            <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-72h (Part II)</title>
          <description>AUC0-72h (area under the concentration-time curve of the analyte of BI 691751 in plasma over the time interval from 0 to 72 h) (part II).
PPS-BA included all subjects in the TS who were randomised to the BA part, who provided at least one observation for at least one primary endpoint, had no important protocol violations relevant for the statistical evaluation of BA and did not experience emesis at or before twice the median tmax.</description>
          <population>Per protocol set for evaluation of bioavailability (PPS-BA). Only subjects with calculable PK parameter were analysed.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2740" spread="26.1"/>
                    <measurement group_id="O2" value="3050" spread="20.5"/>
                    <measurement group_id="O3" value="2800" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Only extensive CYP2D6 metabolisers were selected: 12 (all) subjects of group 'BI 691751 tablet extensive metabolizers (part II)' and 7 (all investigated) subjects of group 'BI 691751 solution (part II) '.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio (net)</param_type>
            <param_value>97.88</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.963</ci_lower_limit>
            <ci_upper_limit>119.809</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'BI 691751 tablet extensive metabolizers (part II)' divided by the geometric mean of 'BI 691751 solution (part II)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of poor metabolisers (5 (all) subjects of group 'BI 691751 tablet poor metabolizers (part II)') and extensive metabolisers (12 (all) subjects of group 'BI 691751 tablet extensive metabolizers (part II)').</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio (net)</param_type>
            <param_value>111.20</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.596</ci_lower_limit>
            <ci_upper_limit>139.576</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of the poor metabolisers divided by the geometric mean of the extensive metabolisers.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Part II)</title>
        <description>Cmax (maximum measured concentration of the analyte of BI 691751 in plasma) (part II)</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug administration</time_frame>
        <population>PPS-BA. Only subjects with calculable PK parameter were analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751 Tablet Extensive Metabolizers (Part II)</title>
            <description>single dose given as 1 tablet; extensive metabolizers; BI 691751: 1 tablet (10 mg)</description>
          </group>
          <group group_id="O2">
            <title>BI 691751 Tablet Poor Metabolizers (Part II)</title>
            <description>single dose given as 1 tablet; poor metabolizers; BI 691751: 1 tablet (10 mg)</description>
          </group>
          <group group_id="O3">
            <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
            <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Part II)</title>
          <description>Cmax (maximum measured concentration of the analyte of BI 691751 in plasma) (part II)</description>
          <population>PPS-BA. Only subjects with calculable PK parameter were analysed.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" spread="33.6"/>
                    <measurement group_id="O2" value="207" spread="31.3"/>
                    <measurement group_id="O3" value="220" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Only extensive CYP2D6 metabolisers were selected: 12 (all) subjects of group 'BI 691751 tablet extensive metabolizers (part II)' and 7 (all investigated) subjects of group 'BI 691751 solution (part II) '.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio (net)</param_type>
            <param_value>101.31</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>28.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.593</ci_lower_limit>
            <ci_upper_limit>127.351</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'BI 691751 tablet extensive metabolizers (part II)' divided by the geometric mean of 'BI 691751 solution (part II)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of poor metabolisers (5 (all) subjects of group 'BI 691751 tablet poor metabolizers (part II)') and extensive metabolisers (12 (all) subjects of group 'BI 691751 tablet extensive metabolizers (part II)').</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio (net)</param_type>
            <param_value>92.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>33.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.662</ci_lower_limit>
            <ci_upper_limit>125.119</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of the poor metabolisers divided by the geometric mean of the extensive metabolisers.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Part I)</title>
        <description>Cmax (maximum measured concentration of BI 691751 in plasma) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
        <time_frame>for dose 1 &amp; 2: up to 168h, for dose 3 &amp; 4: up to 240h, for dose 5 to 8: up to 720h</time_frame>
        <population>Per protocol set for evaluation of dose proportionality (PPS-DP): This subject set includes all subjects of the TS who were randomised to active treatment in the single rising dose part or BA part, and had no important PVs relevant for the statistical evaluation of dose proportionality. Only subjects with calculable PK parameter were analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751 Dose 1 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
          </group>
          <group group_id="O2">
            <title>BI 691751 Dose 2 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
          </group>
          <group group_id="O3">
            <title>BI 691751 Dose 3 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
          </group>
          <group group_id="O4">
            <title>BI 691751 Dose 4 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
          </group>
          <group group_id="O5">
            <title>BI 691751 Dose 5 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
          </group>
          <group group_id="O6">
            <title>BI 691751 Dose 6 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
          </group>
          <group group_id="O7">
            <title>BI 691751 Dose 7 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
          </group>
          <group group_id="O8">
            <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
            <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Part I)</title>
          <description>Cmax (maximum measured concentration of BI 691751 in plasma) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
          <population>Per protocol set for evaluation of dose proportionality (PPS-DP): This subject set includes all subjects of the TS who were randomised to active treatment in the single rising dose part or BA part, and had no important PVs relevant for the statistical evaluation of dose proportionality. Only subjects with calculable PK parameter were analysed.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="15.5"/>
                    <measurement group_id="O2" value="18.3" spread="39.3"/>
                    <measurement group_id="O3" value="88.9" spread="59.1"/>
                    <measurement group_id="O4" value="729" spread="21.5"/>
                    <measurement group_id="O5" value="1320" spread="31.5"/>
                    <measurement group_id="O6" value="3320" spread="46.7"/>
                    <measurement group_id="O7" value="4180" spread="22.2"/>
                    <measurement group_id="O8" value="220" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This was non-confirmatory testing.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>1.0233</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8265</ci_lower_limit>
            <ci_upper_limit>1.2201</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-infinity (Part I)</title>
        <description>AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 extrapolated to infinity) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
        <time_frame>for dose 1 &amp; 2: up to 168 hours (h), for dose 3 &amp; 4: up to 240h, for dose 5 to 8: up to 720h</time_frame>
        <population>PPS-DP. Only subjects with calculable PK parameter were analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751 Dose 1 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
          </group>
          <group group_id="O2">
            <title>BI 691751 Dose 2 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
          </group>
          <group group_id="O3">
            <title>BI 691751 Dose 3 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
          </group>
          <group group_id="O4">
            <title>BI 691751 Dose 4 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
          </group>
          <group group_id="O5">
            <title>BI 691751 Dose 5 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
          </group>
          <group group_id="O6">
            <title>BI 691751 Dose 6 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
          </group>
          <group group_id="O7">
            <title>BI 691751 Dose 7 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
          </group>
          <group group_id="O8">
            <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
            <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity (Part I)</title>
          <description>AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 extrapolated to infinity) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
          <population>PPS-DP. Only subjects with calculable PK parameter were analysed.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1140" spread="34.5"/>
                    <measurement group_id="O4" value="7250" spread="15.9"/>
                    <measurement group_id="O5" value="11900" spread="27.2"/>
                    <measurement group_id="O6" value="24500" spread="20.0"/>
                    <measurement group_id="O7" value="41000" spread="26.9"/>
                    <measurement group_id="O8" value="3630" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality of BI 691751 was explored using a power model (regression model applied to log-transformed data).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This was non-confirmatory testing.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>0.9686</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8107</ci_lower_limit>
            <ci_upper_limit>1.1266</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz</title>
        <description>AUC0-tz (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 up to the last quantifiable data point) (Part I and Part II)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
        <time_frame>Part 1: for dose 1 &amp; 2: up to 168 hours (h), for dose 3 &amp; 4: up to 240h, for dose 5 to 7: up to 720h; Part 2: up to 720h</time_frame>
        <population>PPS-DP for part I and PPS-BA for part II. Only subjects with calculable PK parameter were analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751 Dose 1 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
          </group>
          <group group_id="O2">
            <title>BI 691751 Dose 2 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
          </group>
          <group group_id="O3">
            <title>BI 691751 Dose 3 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
          </group>
          <group group_id="O4">
            <title>BI 691751 Dose 4 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
          </group>
          <group group_id="O5">
            <title>BI 691751 Dose 5 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
          </group>
          <group group_id="O6">
            <title>BI 691751 Dose 6 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
          </group>
          <group group_id="O7">
            <title>BI 691751 Dose 7 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
          </group>
          <group group_id="O8">
            <title>BI 691751 Tablet Extensive Metabolizers (Part II)</title>
            <description>single dose given as 1 tablet; extensive metabolizers; BI 691751: 1 tablet (10 mg)</description>
          </group>
          <group group_id="O9">
            <title>BI 691751 Tablet Poor Metabolizers (Part II)</title>
            <description>single dose given as 1 tablet; poor metabolizers; BI 691751: 1 tablet (10 mg)</description>
          </group>
          <group group_id="O10">
            <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
            <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz</title>
          <description>AUC0-tz (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 up to the last quantifiable data point) (Part I and Part II)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
          <population>PPS-DP for part I and PPS-BA for part II. Only subjects with calculable PK parameter were analysed.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="29.5" spread="18.4"/>
                    <measurement group_id="O3" value="791" spread="45.4"/>
                    <measurement group_id="O4" value="6310" spread="15.4"/>
                    <measurement group_id="O5" value="11400" spread="28.3"/>
                    <measurement group_id="O6" value="24100" spread="21.1"/>
                    <measurement group_id="O7" value="40500" spread="27.2"/>
                    <measurement group_id="O8" value="3150" spread="32.0"/>
                    <measurement group_id="O9" value="3460" spread="17.4"/>
                    <measurement group_id="O10" value="3300" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Only extensive CYP2D6 metabolisers were selected: 12 (all) subjects of group 'BI 691751 tablet extensive metabolizers (part II)' and 7 (all investigated) subjects of group 'BI 691751 solution (part II) '.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio (net)</param_type>
            <param_value>95.48</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.414</ci_lower_limit>
            <ci_upper_limit>122.511</ci_upper_limit>
            <estimate_desc>The geometric mean ratio is calculated as the geometric mean of 'BI 691751 tablet extensive metabolizers (part II)' divided by the geometric mean of 'BI 691751 solution (part II)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Comparison of poor metabolisers (5 (all) subjects of group 'BI 691751 tablet poor metabolizers (part II)') and extensive metabolisers (12 (all) subjects of group 'BI 691751 tablet extensive metabolizers (part II)').</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio (net)</param_type>
            <param_value>109.80</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>28.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.376</ci_lower_limit>
            <ci_upper_limit>142.894</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of the poor metabolisers divided by the geometric mean of the extensive metabolisers.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This was non-confirmatory testing.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>1.0312</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.833</ci_lower_limit>
            <ci_upper_limit>1.1790</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 (Part I)</title>
        <description>t1/2 (terminal half-life of the analyte of BI 691751 in plasma) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
        <time_frame>for dose 1 &amp; 2: up to 168 hours (h), for dose 3 &amp; 4: up to 240h, for dose 5 to 8: up to 720h</time_frame>
        <population>Pharmacokinetic (PK) set (PKS) which includes all subjects of the treated set were were randomised to active treatment in the single rising dose part of bioavailability part, and had no important protocol violations relevant for the statistical evaluation of further PK parameters. Only subjects with calculable PK parameter were analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751 Dose 1 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
          </group>
          <group group_id="O2">
            <title>BI 691751 Dose 2 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
          </group>
          <group group_id="O3">
            <title>BI 691751 Dose 3 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
          </group>
          <group group_id="O4">
            <title>BI 691751 Dose 4 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
          </group>
          <group group_id="O5">
            <title>BI 691751 Dose 5 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
          </group>
          <group group_id="O6">
            <title>BI 691751 Dose 6 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
          </group>
          <group group_id="O7">
            <title>BI 691751 Dose 7 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
          </group>
          <group group_id="O8">
            <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
            <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 (Part I)</title>
          <description>t1/2 (terminal half-life of the analyte of BI 691751 in plasma) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
          <population>Pharmacokinetic (PK) set (PKS) which includes all subjects of the treated set were were randomised to active treatment in the single rising dose part of bioavailability part, and had no important protocol violations relevant for the statistical evaluation of further PK parameters. Only subjects with calculable PK parameter were analysed.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="65.4" spread="37.8"/>
                    <measurement group_id="O4" value="97.4" spread="63.3"/>
                    <measurement group_id="O5" value="74.9" spread="49.2"/>
                    <measurement group_id="O6" value="57.2" spread="34.3"/>
                    <measurement group_id="O7" value="78.3" spread="16.9"/>
                    <measurement group_id="O8" value="59.4" spread="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (Part I)</title>
        <description>tmax (time from dosing to maximum measured concentration of BI 691751) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
        <time_frame>for dose 1 &amp; 2: up to 168 hours (h), for dose 3 &amp; 4: up to 240h, for dose 5 to 8: up to 720h</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751 Dose 1 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
          </group>
          <group group_id="O2">
            <title>BI 691751 Dose 2 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
          </group>
          <group group_id="O3">
            <title>BI 691751 Dose 3 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
          </group>
          <group group_id="O4">
            <title>BI 691751 Dose 4 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
          </group>
          <group group_id="O5">
            <title>BI 691751 Dose 5 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
          </group>
          <group group_id="O6">
            <title>BI 691751 Dose 6 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
          </group>
          <group group_id="O7">
            <title>BI 691751 Dose 7 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
          </group>
          <group group_id="O8">
            <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
            <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Part I)</title>
          <description>tmax (time from dosing to maximum measured concentration of BI 691751) (part I)
Time frame:
Dose 1 and 2: 1 hour (h) before drug administration (admin) and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h and 168h after drug admin
Dose 3 and 4: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h (dose group 4 only), 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h and 240h after drug admin
Dose 5 to 7: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 336h, 432h, 528h, 624h and 720h after drug admin
Dose 8: 1h before drug admin and 20 min, 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 216h, 384h, 552h and 720h after drug admin</description>
          <population>PKS</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.667" lower_limit="0.333" upper_limit="0.667"/>
                    <measurement group_id="O2" value="0.667" lower_limit="0.350" upper_limit="0.667"/>
                    <measurement group_id="O3" value="0.842" lower_limit="0.333" upper_limit="2.02"/>
                    <measurement group_id="O4" value="0.500" lower_limit="0.333" upper_limit="0.667"/>
                    <measurement group_id="O5" value="0.350" lower_limit="0.333" upper_limit="0.667"/>
                    <measurement group_id="O6" value="0.667" lower_limit="0.333" upper_limit="1.50"/>
                    <measurement group_id="O7" value="0.667" lower_limit="0.333" upper_limit="1.02"/>
                    <measurement group_id="O8" value="0.667" lower_limit="0.333" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Subjects With Drug-related Adverse Events (Part I)</title>
        <description>Frequency of subjects with drug-related Adverse Events (AEs) (Part I)</description>
        <time_frame>Part I: 'Day1 to Day21 for Dose 1, 2,3 &amp;4 and Day1 to Day45 for Dose group 5,6 &amp; 7</time_frame>
        <population>Treated Set (TS): all subjects who were documented to have taken at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part I)</title>
            <description>placebo solution
Placebo: placebo solution</description>
          </group>
          <group group_id="O2">
            <title>BI 691751 Dose 1 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
          </group>
          <group group_id="O3">
            <title>BI 691751 Dose 2 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
          </group>
          <group group_id="O4">
            <title>BI 691751 Dose 3 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
          </group>
          <group group_id="O5">
            <title>BI 691751 Dose 4 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
          </group>
          <group group_id="O6">
            <title>BI 691751 Dose 5 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
          </group>
          <group group_id="O7">
            <title>BI 691751 Dose 6 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
          </group>
          <group group_id="O8">
            <title>BI 691751 Dose 7 (Part I)</title>
            <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Subjects With Drug-related Adverse Events (Part I)</title>
          <description>Frequency of subjects with drug-related Adverse Events (AEs) (Part I)</description>
          <population>Treated Set (TS): all subjects who were documented to have taken at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day1 to Day21 for Dose group 1, 2,3 &amp; 4 and Day1 to Day45 for Dose group 5,6 &amp; 7. Part II: Day1 to Day 45.</time_frame>
      <desc>Subjects randomised to 0.5 mg sol. or 1.5 mg sol. were planned by the CTP to be observed for 8 to 21 days, subjects randomised to 5 mg sol. or 15 mg sol. for 11 to 21 days, and subjects randomised to 10 mg sol., 10 mg tab., 30 mg sol., 60 mg sol., or 90 mg sol. for 31 to 45 days after treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Part I)</title>
          <description>placebo solution
Placebo: placebo solution</description>
        </group>
        <group group_id="E2">
          <title>BI 691751 Dose 1 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 1 (0.5 mg powder)</description>
        </group>
        <group group_id="E3">
          <title>BI 691751 Dose 2 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 2 (1.5 mg powder)</description>
        </group>
        <group group_id="E4">
          <title>BI 691751 Dose 3 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 3 (5 mg powder)</description>
        </group>
        <group group_id="E5">
          <title>BI 691751 Dose 4 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 69175, dose 4 (15 mg powder)</description>
        </group>
        <group group_id="E6">
          <title>BI 691751 Dose 5 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 5 (30 mg powder)</description>
        </group>
        <group group_id="E7">
          <title>BI 691751 Dose 6 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 6 (60 mg powder)</description>
        </group>
        <group group_id="E8">
          <title>BI 691751 Dose 7 (Part I)</title>
          <description>single dose given as oral solution
BI 691751: oral solution BI 691751, dose 7 (90 mg powder)</description>
        </group>
        <group group_id="E9">
          <title>BI 691751 Tablet (Part II)</title>
          <description>single dose given as 1 tablet
BI 691751: 1 tablet (10 mg)</description>
        </group>
        <group group_id="E10">
          <title>BI 691751 Solution (Part II); Extensive Metabolizers</title>
          <description>single dose given as oral solution BI 691751: oral solution (10 mg)
5 subjects had no measurable concentration of BI 691751 because a drug-free solution has been administered by mistake. Therefore their results were excluded from all analyses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

